Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
NUP98::NSD1 is one of the most recurring nucleoporin 98 (NUP98) fusions in acute myeloid leukemia (AML). NUP98::NSD1 positive AML is often associated with adverse outcomes and poor response to conventional treatments. However, limited studies have been done to identify new potential targets to develop better treatment approaches. The C-type lectin domain family 12 member A (CLEC12A) is a cell surface receptor that is differentially expressed in leukemic stem cells compared with healthy hematopoietic stem cells. We found a strong CLEC12A overexpression in both NUP98::NSD1 patients and murine AML cells transformed with the NUP98::NSD1 fusion oncogene. To understand the role of Clec12a in NUP98::NSD1 AML, we depleted Clec12a expression in NUP98::NSD1+NRASG12D-immortalized cells using the CRISPR/Cas9 approach. NUP98::NSD1+NRASG12D/Clec12a knockout cells had higher apoptosis levels and lower colony numbers in vitro compared with NUP98::NSD1+NRASG12D/Clec12a wild-type cells. Importantly, the deletion of Clec12a significantly reduced leukemic engraftment and prolonged survival of the NUP98::NSD1+NRASG12D murine model. Our data suggest to further explore CLEC12A as a potential target for the treatment of NUP98::NSD1 AML.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12332935 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2024015739 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia.
Ann Hematol
April 2025
Department of Hematology, The 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army, Nanning, Guangxi, China.
Nucleoporin 98 (NUP98) fusion oncoproteins are associated with various hematologic malignancies. Acute myeloid leukemia (AML) with NUP98-NSD1 typically co-occurs with FLT3-ITD mutations, exhibiting poor initial responses to traditional chemotherapy. This case report describes a relapsed and refractory AML case co-expressing NUP98/NSD1 and FLT3/ITD after matched sibling haplo-identical allogeneic hematopoietic stem cell transplantation, achieving molecular remission with a salvage therapy combining selinexor, venetoclax, and azacitidine.
View Article and Find Full Text PDFPrognostic importance of NUP98-rearrangements in acute myeloid leukemia: A systematic review and meta-analysis.
Caspian J Intern Med
August 2024
Department of Laboratory Hematology and Blood Banking, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Article Synopsis
- NUP98 gene fusions in acute myeloid leukemia (AML) are important for understanding patient outcomes, prompting a detailed meta-analysis to investigate their prognostic implications.
- The study reviewed 15 publications involving 6142 participants to assess the effects of NUP98 rearrangements on overall survival (OS) and event-free survival (EFS), utilizing statistical software for analysis.
- Findings indicate that specific fusions like NUP98-NSD1 and NUP98-KDM5A are linked to significantly poorer outcomes in AML patients, supporting the idea of using these fusions as prognostic indicators.
Treatment of three pediatric AML co-expressing NUP98-NSD1, FLT3-ITD, and WT1.
BMC Pediatr
July 2024
Department of Hematology, The Affiliated Children's Hospital of Kunming Medical University, Kunming Medical University, Kunming, China.
During the treatment of 89 pediatric patients with Acute Myeloid Leukemia (AML) at the Hematology Department of Kunming Medical University's Children's Hospital from 2020 to 2023, three patients were identified to co-express the NUP98-NSD1, FLT3-ITD, and WT1 gene mutations. The bone marrow of these three patients was screened for high-risk genetic mutations using NGS and qPCR at the time of diagnosis. The treatment was administered following the China Children's Leukemia Group (CCLG)-AML-2019 protocol.
View Article and Find Full Text PDFComprehensive molecular and clinical characterization of fusions in pediatric acute myeloid leukemia.
Haematologica
August 2023
Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA; Children's Oncology Group, Monrovia, CA, USA; Division of Hematology and Oncology, Seattle Children's Hospital, Seattle, WA.
NUP98 fusions comprise a family of rare recurrent alterations in AML, associated with adverse outcomes. In order to define the underlying biology and clinical implications of this family of fusions, we performed comprehensive transcriptome, epigenome, and immunophenotypic profiling of 2,235 children and young adults with AML and identified 160 NUP98 rearrangements (7.2%), including 108 NUP98-NSD1 (4.
View Article and Find Full Text PDFGenetic Characteristics According to Subgroup of Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
J Clin Med
April 2022
Catholic Genetic Laboratory Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Article Synopsis
- The study investigates genetic abnormalities in 45 patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), focusing on gene fusions and mutations.
- It identifies four gene fusions and 81 somatic mutations, with TP53 being the most common mutation related to poor survival outcomes.
- Additional mutations (ASXL1 and SRSF2) are noted as potential diagnostic markers for AML-MRC, highlighting their significance in assessing the severity and treatment strategies for the condition.